More Info on the Correlation of Rash with Outcome on EGFR Inhibitors: My Changing View in Light of the TOPICAL Trial
There's been a theme with the inhibitors of the epidermal growth factor receptor (EGFR) -- both oral tyrosine kinase inhibitors (TKIs) and IV monoclonal antibodies -- that the patients who demonstrate good results with these agents tend to get a rash, while the patients who don't get a rash do poorly.